Deep Learning Market Overview

The current deep learning market landscape features the presence of over 70 players that are actively engaged in offering deep learning technologies / services for the purpose of drug discovery. The global deep learning market size is estimated to grow from USD 3.6 billion in 2023 to USD 34.5 billion by 2035, representing a CAGR of 21.9%.

It is worth mentioning that majority of the small players (67%) prefer to operate as technology / software providers. A similar trend can be observed for mid-sized companies. In contrast, most of the very large players (83%) claim to operate as service provider in this domain.

The players offering deep learning-powered technologies / services for drug discovery were analyzed across several relevant parameters, such as year of establishment, company size and location of headquarters, along with the information on companies’ service and product centric models. Majority of the players in this domain claim to offer technology / software as a service. An equal share of players offer deep learning solutions through research / discovery partnerships. It is worth noting that companies have recently started offering contract research services / fee for service model to support deep learning-based drug discovery initiatives.

Deep Learning Market Segmentation

Key segments of deep learning market are Oncological Disorders, Infectious Diseases, Neurological Disorders, Immunological Disorders, Endocrine Disorders, Cardiovascular Disorders, Respiratory Disorders, Eye Disorders, Musculoskeletal Disorders, Inflammatory Disorders and Other Disorders. Further, It is worth mentioning that there has been a steady increase in the number companies providing deep-learning powered drug discovery services / platforms. In fact, more than 45% players were established post 2015. This can be attributed to the rising interest of industry stakeholders towards the implementation of advanced technologies in the drug discovery process. Examples of recently established firms include (in alphabetical order; established post-2020) Cortex Discovery (2021), Ensem Therapeutics (2021), Isomorphic Labs (2021) and Merative (2022).

It is worth highlighting that big data has emerged as the primary driver for the implementation of advanced deep learning technologies for the purpose of drug discovery.The current deep learning market landscape features the presence of over 130 players that are actively engaged in offering deep learning technologies / services for the purpose of diagnostics.

Deep Learning Market Geographical Regions

Key Geographical Regions of Deep Learning Market are North America, Europe, Asia Pacific, Rest of the World. Majority of the small players (81%) offer image processing solutions using their deep learning technologies, followed by cloud-based solutions (65%). It is worth highlighting that biomarker identification services are predominantly offered by mid-sized players engaged in the deep learning domain.

The players offering deep learning-powered technologies / services for drug discovery were analyzed across several relevant parameters.

Deep Learning Market Key Companies

Key Companies involved in deep learning market are Aegicare, Aiforia Technologies, Ardigen, Berg, Google, Huawei, Merative , Nference, Nvidia, Owkin, Phenomic AI, Pixel AI. Most of the solutions are being used for analyzing CT images, followed by those employed for processing MRI images, ultrasound and X-ray images. It is worth highlighting that majority of the stakeholders have the required deep learning expertise for discovery of candidates targeting oncological (62%), followed by neurological disorders (37%).  Examples of firms capable of enabling deep learning in diagnostics for therapies targeting neurological disorders include (in alphabetical order) Aidoc, BERG, DeepScopy, icometrix and Keya Medical.

Browse Complete Report at https://www.rootsanalysis.com/reports/deep-learning-in-drug-discovery-market/156.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organizations worldwide.

All our analysts are trained to produce high-quality research work. They are continuously mentored by senior experts to present an original, unbiased and informed perspective on pressing issues in the industry. On any particular subject, we bring together the best available resources to ensure highest quality in all our reports.

Contact Details

Roots Analysis 

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com 

Website: https://www.rootsanalysis.com/